Opinion|Videos|September 22, 2023
Available Frontline Treatment Options for Patients With Advanced or Recurrent Endometrial Cancer
Author(s)Ramez N. Eskander, MD, Krishnansu Tewari, MD
Krishnansu Tewari, MD, details the first-line treatment options for patients with recurrent endometrial cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Sapanisertib and serabelisib plus paclitaxel received FDA fast track designation for pretreated advanced PI3K/AKT/mTOR pathway–altered endometrial cancer.
Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in ovarian and endometrial cancer.
Advertisement
Advertisement
Trending on OncLive
1
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
2
T-DXd Improves PFS in First-Line HER2-Mutant NSCLC
3
FDA Grants Fast Track Designation to Sapanisertib and Serabelisib Plus Paclitaxel in Advanced Endometrial Cancer
4
Adding SBRT to Nivolumab/Ipilimumab Fails to Improve Outcomes in mCRPC
5